Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M1 Malaria Vaccine in Healthy African Women of Childbearing Potential
NCT06080243Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of R21/Matrix-M in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Incidence of local and systemic solicited adverse events and Number of participants with P falciparum infection. Started Mar 2025; status: active, not recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06080243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080243.